MedTrace Logo

CAPOXIRI+Bevacizumab vs. FOLFOXIRI+Bevacizumab for mCRC

NCT04097444 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 112

Last updated 2019-10-31

No results posted yet for this study

Summary

The objective is to compare the efficacy and safety of CAPOXIRI+BEV therapy versus FOLFOXIRI+BEV therapy as first-line therapy in patients with metastatic colorectal cancer (mCRC).

Conditions

Interventions

BIOLOGICAL

Bevacizumab

Given IV

DRUG

5-fluorouracil

Given IV

DRUG

Leucovorin calcium

Given IV

DRUG

Irinotecan hydrochloride

Given IV

DRUG

Oxaliplatin

Given IV

DRUG

Capecitabine

Given PO

Sponsors & Collaborators

  • Chugai Pharmaceutical

    lead INDUSTRY

Principal Investigators

  • Takeshi Kato, M.D., Ph.D. · Department of Surgery, National Hospital Organization Osaka National Hospital.

  • Akihito Tsuji, M.D., Ph.D. · Department of Medical Oncology, Kagawa University Hospital.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-11
Primary Completion
2022-08-31
Completion
2022-08-31

Countries

  • Japan

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04097444 on ClinicalTrials.gov